EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Atsushi Naganuma iD, Satoru Kakizaki iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Takeshi Hatanaka iD, Kazuya Kariyama iD, Joji Tani, Masanori Atsukawa iD, Koichi Takaguchi iD, Ei Itobayashi iD, Shinya Fukunishi, Kunihiko Tsuji iD und 31 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Atsushi Naganuma und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aims to investigate the clinical utility of the derived neutrophil‐to‐lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable hepatocellular carcinoma (HCC) undergoing combination therapy with atezolizumab and bevacizumab (Atez/Bev).

Methods

A retrospective analysis was conducted on 310 patients. The dNLR, NLR, and GNRI were calculated, and their impact on progression‐free survival (PFS) and overall survival (OS) was assessed. The formula for calculating dNLR is: (neutrophil count ÷ [white blood cell count—neutrophil count]), which means it does not require lymphocyte count. Furthermore, GNRI‐dNLR and GNRI‐NLR scores were defined, and their prognostic values were also analyzed.

Results

The median PFS of this cohort was 7.2 months (95% CI: 5.9–8.5), and the median OS was 24.9 months (95% CI: 19.6–30.2). The dNLR, NLR, and GNRI were significant predictors of both PFS and OS. The dNLR showed a significant correlation with the NLR (Pearson correlation coefficient, p < 0.0001). Patients with high GNRI‐dNLR scores demonstrated significantly worse PFS and OS compared to those with low scores ( p = 0.001, p < 0.001, respectively). Compared to stratification by GNRI alone, the GNRI‐dNLR or GNRI‐NLR provided better stratification for both PFS and OS.

Conclusion

The dNLR could be a valuable substitute for NLR as a prognostic marker in patients with unresectable HCC undergoing Atez/Bev therapy. It offers a feasible alternative for databases lacking lymphocyte count information, ensuring comprehensive patient stratification and outcome prediction. The GNRI‐NLR or GNRI‐dNLR score provided better stratification compared to GNRI alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntineoplastic Combined Chemotherapy ProtocolsNeutrophilsLymphocytesHumansMaleFemaleAgedRetrospective StudiesAntibodies, Monoclonal, HumanizedMiddle AgedAged, 80 and overPrognosisTreatment OutcomeAdultLeukocyte CountLymphocyte Count

Stichwörter der Autor:innen

GNRIdNLRhepatocellular carcinomaimmune checkpoint inhibitorprognosis

Substanzen

atezolizumabBevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.
  • Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
  • Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.

ORCID-Profile: Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Takeshi Hatanaka, Kazuya Kariyama, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Zitieren

APA

Naganuma, A., Kakizaki, S., Hiraoka, A., Tada, T., Hatanaka, T., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Toyoda, H., Ogawa, C., Nishikawa, H., Nishimura, T., Kawata, K., …, & Kumada, T. (2025). Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70618

Vancouver

Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al. Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70618

BibTeX
@article{Naganuma2025,
  author = {Naganuma, Atsushi and Kakizaki, Satoru and Hiraoka, Atsushi and Tada, Toshifumi and Hatanaka, Takeshi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Toyoda, Hidenori and Ogawa, Chikara and Nishikawa, Hiroki and Nishimura, Takashi and Kawata, Kazuhito and Kosaka, Hisashi and Hirooka, Masashi and Yata, Yutaka and Ohama, Hideko and Kuroda, Hidekatsu and Matono, Tomomitsu and Aoki, Tomoko and Kanayama, Yuki and Tanaka, Kazunari and Tada, Fujimasa and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Imai, Michitaka and Nakamura, Shinichiro and Enomoto, Hirayuki and Kaibori, Masaki and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi},
  title = {Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70618}
}
Kostenlos starten →